Form 4: Acumen CFO Sells Shares for Tax Obligations

Acumen Pharmaceuticals' CFO and Chief Business Officer, Matt Zuga, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Matt Zuga, CFO & Chief Business Officer of Acumen Pharmaceuticals, Inc. (ABOS), reported sales of common stock.
• On January 21, 2026, 2,473 shares were sold at a weighted average price of $1.8072 per share, with prices ranging from $1.7650 to $1.8700.
• On January 22, 2026, an additional 1,687 shares were sold at a price of $1.86 per share.
• These sales were automatic 'sell to cover' transactions to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Zuga on August 30, 2024.
• Following these transactions, Mr. Zuga beneficially owns 304,924 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan, which is a common and expected event for executives and generally considered neutral in terms of market sentiment.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and non-discretionary sale, which can reduce concerns about opportunistic insider selling.

Negatives

• The sales resulted in a reduction of direct insider ownership, which, while routine for tax purposes, can sometimes be viewed with slight caution by some investors.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales represent the number of shares sold by the Reporting Person through an automatic 'sell to cover' transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.

Industry Context

This insider transaction report is specific to Acumen Pharmaceuticals and its executive, Matt Zuga. It does not provide broader industry trends or competitive insights.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, though the routine nature of the transaction mitigates significant concern.

Key Dates

Recommendation

The reported transactions are routine 'sell to cover' sales by an executive to satisfy tax obligations upon the vesting of restricted stock units, executed under a pre-arranged Rule 10b5-1 plan. Such transactions are common and do not typically signal a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this filing. Therefore, a 'hold' recommendation is appropriate as this filing does not present new information to alter an existing investment thesis.

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, Insider Transaction, Stock Sale, CFO, Restricted Stock Units, Tax Withholding, Rule 10b5-1